Epidemiology of inflammatory bowel disease in Poland 2009-2020: nationwide data

Zagórowicz, Edyta; Walkiewicz, Dorota; Kucha, Piotr; Perwieniec, Jakub; Maluchnik, Michał; Wieszczy, Paulina; Reguła, Jarosław

doi:10.20452/pamw.16194

Cited by 19 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We searched records for health services taking the form of individually reported claims to the NFZ by service providers. The initial assessment concerned the prevalence of IBD in Poland in the years 2012-2020, by reference to prevalent and incident cases in the NFZ database assigned a K50 or K51 diagnosis, in line with the International Statistical Classification of Diseases and Related Health Problems (ICD-10) [8]. Due to a lack of electronic data, there was no possibility of assessing the prevalence of IBD for the years 2008-2011, a period in which the CD therapeutic program was already active.…”

Section: Data Sourcementioning

confidence: 99%

“…As a basis for calculating the percentages of patients receiving biologic drugs for CD or UC, we used the respective prevalences for those diseases, as estimated previously [8]. Individuals were selected based on the following criteria: (1) at least two services in hospital, or outpatient specialist care, reported with the K50 or K51 ICD-10 codes and either (2) at least two prescriptions filled out for IBD drugs (as listed in Supplementary material, Table S2) and with an interval between of at least two months, or (3) an episode of intestinal surgery assigned one of the defined ICD-9 codes (Supplementary material, Table S3), prior to at least one service reported with K50 or K51 ICD-10 codes.…”

Section: Prevalences Of CD and Ucmentioning

confidence: 99%

“…According to The Global Burden of Diseases, Injuries and Risk Factors Study, there were 6.8 million people living with IBD in 2017 [7]. In 2020, Poland reported 23 574 patients diagnosed with CD, as well as 73 235 with UC [8], out of a national population of some 38 million inhabitants.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Biologic treatment of inflammatory bowel disease in Poland, 2012–2020: nationwide data

Kucha¹,

Zagórowicz²,

Walkiewicz³

et al. 2022

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

To the best of our knowledge, this article is the first to describe the population of Polish patients suffering from inflammatory bowel diseases (IBDs) and treated with innovative biologic drugs, which are the best treatment options known for patients with moderate to severe disease courses. Using administrative data, we estimate and discuss the significant differences in the use of biologic drugs across different regions of the country. We also show a higher treatment rate for men, compared to women, as well as a high and growing rate for the youngest population. Access to modern therapies is crucial for improving quality of life for the substantially growing population of IBD patients. We believe our work will be a helpful reference for evaluating the current situation of those patients and for predicting future demands.

show abstract

Section: Data Sourcementioning

confidence: 99%

Section: Prevalences Of CD and Ucmentioning

confidence: 99%

See 1 more Smart Citation

Biologic treatment of inflammatory bowel disease in Poland, 2012–2020: nationwide data

Kucha¹,

Zagórowicz²,

Walkiewicz³

et al. 2022

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…które jest podawane dożylnie. Infliksymab może być nieznacznie lepszy od adalimumabu i golimumabu, z wyższymi wskaźnikami indukcji remisji i gojenia się błony śluzowej [3,6]. Poziomy leków i przeciwciał przeciwlekowych powinny być mierzone u pacjentów, u których stwierdzono utratę odpowiedzi na lek anty-TNF, w celu ukierunkowania decyzji terapeutycznych (eskalacja dawki lub zmiana na inny lek anty-TNF lub inną klasę leków biologicznych).…”

Section: Standardowe Schematy Terapeutyczneunclassified

“…Dla przykładu, w Niemczech obecnie cierpi na tę chorobę około 150 tysięcy osób [2]. Z kolei wg badania opublikowanego w 2022 roku w Polsce w 2020 roku chorobowość dla WZJG wynosiła 191.4 na 100 000 osób [3]. Klasyfikacja ciężkości rzutów WZJG według zmodyfikowanych kryteriów Truelove'a i Wittsa w wytycznych ECCO 2017 służy do wyboru właściwego leczenia i przedstawia się następująco: 1) lekkie -<4 wypróżnienia z domieszką krwi na dobę, temperatura ciała <37,5°C, częstotliwość rytmu serca <90/min, stężenie hemoglobiny >11,5 g/dl, OB <20 mm po 1 h, CRP w normie 2) ciężkie -≥6 wypróżnień z domieszką krwi na dobę oraz ≥1 z następujących: gorączka >37,8°C, częstotliwość rytmu serca >90/min, stężenie hemoglobiny <10,5 g/dl, OB >30 mm po 1 h, CRP >30 mg/l 3) umiarkowane -≥4 wypróżnienia z krwią na dobę, jeśli temperatura ≤37,8°C, częstotliwość rytmu serca ≤90/min, stężenie hemoglobiny ≥10,5 g/dl, OB ≤30 mm po 1 h, CRP ≤30 mg/l (cechy pośrednie między rzutami lekkim i ciężkim) [4].…”

unclassified

Ulcerative colitis – recent and potential methods of treatment - review

TOMASIK

WARZYSZAK

MAŁEK

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and purpose: Ulcerative colitis (UC, colitis ulcerosa) belongs to a group of inflammatory bowel diseases of unexplained etiology. It is a diffuse nonspecific inflammation of the mucosa of the rectum or rectum and colon, leading to ulceration in more severe cases. Despite a decline in the incidence of ulcerative colitis in developed countries, the prevalence continues to rise due to increasingly predominant benign course of the disease with a low mortality rate. The purpose of this review is to summarize latest directions and discoveries in research of ulcerative colitis. Materials and methods: This review is based on articles published in Pubmed between 2017 and 2022 by searching keywords ulcerative colitis treatment, ulcerative colitis guidelines.State of knowledge: Currently, many independent scientific societies represent a consensus position on the standard management of patients with UC, while recent therapeutic options are constantly emerging due to intensive research. These options require the involvement of multiple medical centers to determine their position in future guidelines.Conclusion: Although ulcerative colitis is a disease that is diagnosed and detected relatively easily, due to its chronic nature, relatively high prevalence in the population and lack of causal treatment options, it is an important direction for further research.

show abstract

Savings in social expenditures for work incapacity in patients with inflammatory bowel disease depend on access to innovative therapies in Poland

Zagórowicz,

Binowski,

Strządała

et al. 2024

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Objectives Inflammatory bowel diseases (IBD) are an increasing burden for societies. We examined Polish Social Insurance Institution (ZUS) work incapacity expenditures for people with IBD compared with the general population. Methods Aggregate data were obtained on ZUS expenditures between 2012 and 2021 in Polish zlotys (PLN). Annual work incapacity benefit expenditures were analyzed and IBD benefit expenditures were examined relative to innovative IBD drug utilization in individual provinces. Results Between 2012 and 2021, annual ZUS expenditures per person increased, while expenditures per IBD patient decreased. Proportionally, absenteeism was the largest ZUS expenditure in the general population, while disability pensions were the largest in the IBD population. ZUS expenditures due to absenteeism in the general population increased by PLN 282 per person; those due to disability pensions decreased by PLN 85. Disability pension spending due to Crohn’s disease (CD) and ulcerative colitis (UC) decreased by PLN 371 and PLN 284, respectively, while absenteeism spending per person with CD and UC decreased (PLN 58 and PLN 35, respectively). Nationwide in 2021, 8.5% of people with CD and 1.9% of those with UC received innovative drugs. The percentage of people receiving innovative drugs and ZUS expenditure per person were inversely related in 9/16 provinces for CD and 5/16 for UC. Conclusion Polish state spending on work incapacity benefits increased in the general population but decreased in people with IBD between 2012 and 2021. Use of innovative drugs was associated with reduced spending per person with IBD in some provinces.

show abstract

Epidemiology of inflammatory bowel disease in Poland 2009-2020: nationwide data

Cited by 19 publications

References 15 publications

Biologic treatment of inflammatory bowel disease in Poland, 2012–2020: nationwide data

Biologic treatment of inflammatory bowel disease in Poland, 2012–2020: nationwide data

Ulcerative colitis – recent and potential methods of treatment - review

Savings in social expenditures for work incapacity in patients with inflammatory bowel disease depend on access to innovative therapies in Poland

Contact Info

Product

Resources

About